Resistance to PD-1/PD-L1 immune checkpoint blockade in advanced non-small cell lung cancer

Critical Reviews in Oncology/Hematology, Journal Year: 2025, Volume and Issue: 209, P. 104683 - 104683

Published: Feb. 28, 2025

Language: Английский

---

The Application of Dendritic Cells Vaccines in Tumor Therapy and Their Combination with Biomimetic Nanoparticles

Vaccines, Journal Year: 2025, Volume and Issue: 13(4), P. 337 - 337

Published: March 21, 2025

Dendritic cells (DCs) act as a bridge between innate and adaptive immunity by presenting antigens to effector immune have shown broad application potential in tumor immunotherapy. However, the clinical translation of DC vaccines encounters significant challenges, such immunosuppressive microenvironment (TME) sub-optimal function vaccine efficacy vivo. In this review, our investigation has uncovered latest developments their cancer immunotherapy, with special emphasis on integration nanotechnology. Several types nanomaterials, including protein cage nanoparticles (NPs), biomimetic NPs, targeted multifunctional been developed enhance antigen presentation ability DCs stimulatory effects T cells. addition, we also summarized synergistic anti-cancer checkpoint inhibitors, chemotherapy, radiotherapy. recent advances nanotechnology made it possible develop novel biomarkers that can capacity stimulate These not only improve accuracy precision design but provide new insights into understanding mechanisms DC-mediated response. Despite challenges pertaining technical complexities individual adaptation production vaccines, personalized immunotherapy based is expected become an important part treatment rapid biotechnology immunology. This review provides perspectives solutions for optimal therapy.

Language: Английский

---

Recent developments in myeloid immune modulation in cancer therapy

Trends in cancer, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 1, 2025

Language: Английский

---

SQYC formula improves the efficacy of PD-1 monoclonal antibodies in MSS colorectal cancer by regulating dendritic cell mitophagy via the PINK1-Parkin pathway

Phytomedicine, Journal Year: 2025, Volume and Issue: 138, P. 156388 - 156388

Published: Jan. 11, 2025

Language: Английский

---

The Extra‐Tumoral Vaccine Effects of Apoptotic Bodies in the Advancement of Cancer Treatment

Small, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 28, 2025

Abstract The induction of apoptosis in tumor cells is a common target for the development anti‐tumor therapies; however, these therapies still leave patients at increased risk disease recurrence. For example, apoptotic can promote growth and immune evasion via secretion metabolites, extracellular vesicles, pro‐tumorigenic macrophages. This paradox effects cell has begged question whether suitable cancer therapy, led to further explorations into other immunogenic death‐based approaches. However, strategies face multiple challenges, most critical which microenvironment. Contrary promotion tolerance mediated by cells, bodies with enriched tumor‐related antigens have demonstrated great potential, as evidenced their ability initiate systemic T‐cell responses. These characteristics indicate that body‐based could be ideal “in situ” extra‐tumoral vaccine candidates treatment cancers, address current issues apoptosis‐based or immunotherapy treatments. Although not yet tested clinically, vaccines potential better patient outcomes future.

Language: Английский

---

Research trends and highlights in PD-1/PD-L1 inhibitor immunotherapy in lung cancer: a bibliometric analysis

Discover Oncology, Journal Year: 2025, Volume and Issue: 16(1)

Published: March 11, 2025

Abstract Background Lung cancer is one of the most common malignant tumors worldwide. This article aims to review current research status and trends in PD-1/PD-L1 inhibitor immunotherapy. Method On basis Web Science Core Collection database, literature on immunotherapy lung patients was searched analyzed for all years up August 5, 2023. Bibliometric techniques were employed, including CiteSpace (6.1.R6), VOSviewer, Bibliometrix package R, examine publication counts, countries, institutions, authors, journals, cited literature, keywords, trends. Results A total 1,252 documents included following screening process. The analysis revealed that China had highest number publications (512), whereas institution with UDICE French Association Research Universities Union (193). journal articles Journal Immunotherapy Cancer (48), prolific author Zhou Caixun from Tongji University (20). Co-citation Borghaei H’s 2015 New England Medicine citation frequency. clustering results indicated frequently referenced keywords predictors, treatment monitoring, hyperprogressive diseases. There a growing trend toward combination therapies, such as dual immune checkpoint inhibitors, into molecular mechanisms within tumor microenvironment, aimed at enhancing efficacy reducing adverse effects. Conclusion indicates inhibitors are pivotal this domain focuses identifying biomarkers addressing evasion resistance maximize efficacy, mitigating

Language: Английский

---

Applications of mRNA Delivery in Cancer Immunotherapy

International Journal of Nanomedicine, Journal Year: 2025, Volume and Issue: Volume 20, P. 3339 - 3361

Published: March 1, 2025

Cancer treatment is continually advancing, with immunotherapy gaining prominence as a standard modality that has markedly improved the management of various malignancies. Despite these advancements, efficacy remains variable, certain cancers exhibiting limited response and patient outcomes differing considerably. Thus, enhancing effectiveness imperative. A promising avenue mRNA delivery, employing carriers such liposomes, peptide nanoparticles, inorganic exosomes to introduce cargos encoding tumor antigens, immune-stimulatory, or immune-modulatory molecules into immune microenvironment (TIME). This method aims activate system target eradicate cells. In this review, we characteristics limitations summarize application mechanisms currently prevalent in mRNA-based treatment. Additionally, given significant clinical checkpoint inhibitors (ICIs) chimeric antigen receptor (CAR)-based cell therapies solid tumors (including melanoma, non-small-cell lung cancer, head neck squamous carcinoma, triple-negative breast gastric cancer) leukemia, which have become first-line treatments, highlight discuss recent progress combining delivery ICIs, CAR-T, CAR-NK, CAR-macrophage therapies. combination enhances targeting capabilities ICIs CAR-cell-based therapies, while also mitigating long-term off-target toxicities associated conventional methods. Finally, analyze current systems, nuclease-induced instability, immunogenicity risks, complex carrier production, knowledge gaps concerning dosing safety. Addressing challenges crucial for unlocking potential cancer immunotherapy. Overall, exploring enriches our comprehension holds promise developing personalized effective strategies, potentially responses patients extending their survival time.

Language: Английский

---

Tumor Heterogeneity and the Immune Response in Non-Small Cell Lung Cancer: Emerging Insights and Implications for Immunotherapy

Cancers, Journal Year: 2025, Volume and Issue: 17(6), P. 1027 - 1027

Published: March 19, 2025

Resistance to immune checkpoint inhibitors (ICIs) represents a major challenge for the effective treatment of non-small cell lung cancer (NSCLC). Tumor heterogeneity has been identified as an important mechanism resistance in and increasingly implicated ICI resistance. The diversity clonality tumor neoantigens, which represent target epitopes tumor-specific cells, have shown impact efficacy immunotherapy. Advances genomic techniques further enhanced our understanding clonal landscapes within NSCLC their evolution response therapy. In this review, we examine role during surveillance highlight its spatial temporal revealed by modern technologies. We explore additional sources heterogeneity, including epigenetic metabolic factors, that come under greater scrutiny potential mediators response. finally discuss implications on ICIs strategies overcoming therapeutic

Language: Английский

---

Tissue-specific properties of type 1 dendritic cells in lung cancer: implications for immunotherapy

Journal for ImmunoTherapy of Cancer, Journal Year: 2025, Volume and Issue: 13(3), P. e010547 - e010547

Published: March 1, 2025

Checkpoint inhibitors have led to remarkable benefits in non-small cell lung cancer (NSCLC), yet response rates remain below expectations. High-dimensional analysis and mechanistic experiments clinical samples relevant NSCLC models uncovered the immune composition of tissues, providing invaluable insights into functional properties tumor-infiltrating T cells myeloid cells. Among cells, type 1 conventional dendritic (cDC1s) stand out for their unique ability induce effector CD8 against neoantigens coordinate antitumoral immunity. Notably, resident cDC1 are particularly abundant long-lived express a tissue-specific gene program, underscoring central role Here, we discuss recent on induction regulation responses cancer, separating it from tissue-agnostic knowledge generated heterogeneous tumor models. We focus most studies dissecting states spatial distribution across stages impact neoantigens. Finally, highlight gaps emerging strategies harness immunostimulatory potential.

Language: Английский

---

Antigen-presenting cancer-associated fibroblasts in murine pancreatic tumors differentially control regulatory T cell phenotype and function via CXCL9 and CCL22

bioRxiv (Cold Spring Harbor Laboratory), Journal Year: 2025, Volume and Issue: unknown

Published: April 1, 2025

Pancreatic ductal adenocarcinoma (PDAC) is characterized by a complex tumor microenvironment (TME) including stromal cells that influence resistance to therapy. Recent studies have revealed cancer-associated fibroblasts (CAFs) are heterogeneous in origin, gene expression, and function. Antigen-presenting CAFs (apCAFs), defined major histocompatibility (MHC)-II expression can activate effector CD4 + T the potential contribute anti-cancer immune response, but also induce regulatory cell (Treg) differentiation. Whether apCAFs promote or restrain antitumor response remains uncertain. Using clones of KPC murine PDAC model differing sensitivity checkpoint blockade (ICB), we found immunosensitive (sKPC) tumors were higher apCAF infiltration than resistant (rKPC) tumors. IMC analysis showed proximity both sKPC rKPC implicating interaction within TME. apCAF-depleted tumor-bearing mice had diminished ICB. from activated tumor-infiltrating induced Treg However, transcriptomic Tregs overexpressed for immunosuppressive genes rKPCs relative sKPCs, this associated with differential chemokine signaling depending on origin. Together these data implicate as important mediators modulation which could facilitate development more effective anti-tumor based approaches patients.

Language: Английский

---